new glp 1 drug retatrutide ๐๐ฅ Retatrutide: The Most Powerful Weight-Loss Yet? ๐งฌ๐ Phase 3 clinical results are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, is showing unmatched levels of New GLP-3 drug significantly slashes
Description
L.et al (2020)
Mounjaro also sees substantial price differences, costing around $444 in the Netherlands and $319 in Japan, versus $1,023 in the US
Step up gradually
Abstract Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE
Patients in NY, NJ, PA, and CT typically see appetite reduction within 3-5 days of starting injections, with meaningful weight loss appearing by week 4
